Comparison · NCT00611325-sae
EIAED vs Non-EIAED: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. EIAED vs Non-EIAED: serious adverse events. Trial comparisons, record NCT00611325-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00611325-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.393 | 0.236 | 0.576 | wilson | |
| Risk in group 2 | 0.179 | 0.0788 | 0.356 | wilson | |
| Risk difference, group 1 minus group 2 | 0.214 | -0.0227 | 0.423 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.2 | 0.878 | 5.51 | log | |
| Odds ratio, group 1 over group 2 | 2.98 | 0.871 | 10.2 | log | |
| Number needed to harm, for one more participant with a serious adverse event on EIAED than on Non-EIAED | 4.67 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | EIAED | Avastin: Avastin was administered intravenously at the dose 15 mg/kg every 3 weeks.~Bortezomib: Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, \& 32 of a 42-day cycle. Bortezomib was 2.5 mg/m2 for patients taking EIAEDs. | 11 | 28 | EG000 |
| Group 2 | Non-EIAED | Avastin: Avastin was administered intravenously at the dose 15 mg/kg every 3 weeks.~Bortezomib: Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, \& 32 of a 42-day cycle. Bortezomib was 1.7 mg/m2 for patients not taking EIAEDs. | 5 | 28 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 60 months
Source ClinicalTrials.gov
Trial
- Title
- Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma
- NCT number
- NCT00611325
- Phases
- PHASE2
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Avastin, Bortezomib
- Lead sponsor
- Duke University
- Results first posted
- 2014-02-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00611325?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00611325-sae